Joaquin Seras Franzoso

I am researcher and PI at the Drug Delivery & Targeting Group belonging to the "Advanced Therapies and Advanced Interventions, Nanomedicine, Transplant & Donation - AVANT " eCORE at Vall d'Hebron Institute of Research (VHIR). I combine this main activity with acting as associate lecturer at the Autonomous University of Barcelona (UAB).

Institucions de les que formen part

Investigador/a principal
Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia

Vall Hebron Institut de Recerca

Joaquin Seras Franzoso

Institucions de les que formen part

Investigador/a principal
Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia

Vall Hebron Institut de Recerca

I performed my PhD at the Autonomous University of Barcelona (UAB, 2012). There, I focused on the development of first-in-class biomedical uses for bacterial Inclusion Bodies (IBs). IBs are recombinant protein deposits, between the nano- and micro scale, historically discarded as waste by products of protein production. My research studied the IB-exerted stimuli on mammalian cell interfaces when producing complex nanotopographies for tissue engineering. After my PhD I devoted myself to expand the catalogue of biomedical uses for IBs, as high added value biomaterials. I engineered IBs to be used as depots for the slow release of therapeutic proteins, polyvalent coatings and immunomodulatory particles.
I moved to Vall d'Hebron Research Institute (VHIR) in 2015 awarded with an AECC post-doctoral fellowship. Here, I have continued my work in the nano-sphere. Particularly, I have participated in the development of Polymeric Micelles (PM) for the PM-mediated intracellular delivery of therapeutic antibodies, targeting cancer stem cell intrinsic drug resistance. In parallel, I started to explore the potential of extracellular vesicles (EVs). First, as central mediators of intercellular communication with roles in cancer cell plasticity regulation and premetastatic niche conditioning. Secondly, exploiting EVs capacity as protein delivery systems. In this regard, I focused on the generation of protein therapeutics loaded in vivo into EVs. This approach combines protein production and NP functionalization in a single step with intended applications in rare diseases and cancer therapy.

I have participated in >20 competitive projects with an accumulated funding of > 3 Milion euros (PI of two). This activity rendered >50 articles (hi=25) in international journals and >60 contributions to congresses. Complementing this activity I engaged teaching undergraduates (2010-2012 & 2021 - , AQU Lecturer accreditation) at UAB and mentoring master and PhD students.

Línies de recerca

Estudi de les bases moleculars i cel·lulars del càncer

IP: Joaquin Seras Franzoso

Projectes

Impact of stem-related tumor extracellular vesicles subsets in TNBC progression.

IP: Joaquin Seras Franzoso
Col·laboradors: Maria Fidel Lledò, Miriam Izquierdo Sans
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 119567
Referència: FI23/00223
Durada: 15/01/2024 - 14/01/2028

MycoMatrix: engineering of a recombinant live biotherapeutic to normalise tumour extracellular matrix in KRAS-driven Non-Small Cell Lung Cancer

IP: Ibane Abasolo Olaortua
Col·laboradors: Joaquin Seras Franzoso, Fernanda Raquel Da Silva Andrade
Entitat finançadora: Ministerio de Ciencia e Innovación-MICINN
Finançament: 333099
Referència: CPP2022-009780
Durada: 01/07/2023 - 30/06/2026

Nanoclustered Affimers for Targeted KRAS Ablation in Pancreatic Ductal Adenocarcinoma

IP: Joaquin Seras Franzoso
Col·laboradors: Diana Fernandes de Rafael
Entitat finançadora: Asociación Cáncer de Páncreas
Finançament: 50000
Referència: ACANPAN/PROJECTES/2023/SERAS
Durada: 05/12/2023 - 04/12/2025

TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas

IP: Begoña Benito Villabriga
Col·laboradors: Carmen Escudero Iriarte, Laia Ventura i Expósito, Susana Otero Romero, Ibane Abasolo Olaortua, Ignacio Ferreira González, José Antonio Barrabés Riu, Carlos Nos Llopis, Pablo Velasco Puyó, Jose Fernando Rodríguez Palomares, María Rosario Pérez- Torres Lobato, Sunny Malhotra Sareen, Belen Perez Dueñas, Jaume Sastre Garriga, Joan López Hellin, Antonia Sambola Ayala, Jordi Rio Izquierdo, Nuria Rivas Gandara, Jordi Perez Rodon, Aroa Soriano Fernández, Manuel Comabella Lopez, Antonio Rodríguez Sinovas, Gisela Teixido Tura, Antonia Pijuan Domenech, Roser Ferrer Costa, Joaquin Seras Franzoso, Carmen Tur Gomez, Maria Cristina Díaz de Heredia Rubio, Laia Yañez Bisbe, Julia German Cortes, Maria Jose Pérez García, Miguel Segura Ginard, Diego Baranda Martínez-Abasca, Cristina Auger Acosta, Neus Bellera Gotarda, Herena Eixarch Ahufinger, M Mar Mañu Pereira, Deborah Pareto Onghena, Lorena Valero Arrese, Aitor Uribarri Gonzalez, Jordi Bañeras Rius, Alex Rovira Cañellas, Mar Tintore Subirana, Bruno García del Blanco, Maria Teresa Salcedo Allende, Marisol Ruiz Meana, Ana Belén Méndez Fernández, Xavier Montalban Gairín, Simon Schwartz Navarro, Anna Llort Sales, Carmen Espejo Ruiz, Raquel Hladun Alvaro, Angels Alcina Mila, Sandra Mancilla Zamora, Zamira Vanessa Diaz Riascos, Ana Zabalza de Torres, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Marc Miquel Moltó Abad, Javier Inserte Igual, Luciana Midaglia Fernandez, Elizabeth Pando Rau, Gabriela Guillén Burrieza, Ana Laura Cazurro Gutierrez, David Gómez Andrés, Alvaro Cobo Calvo, Alvaro Calabuig Goena, Joaquin Castillo Justribo, Lydia Dux-Santoy Hurtado, Lucas Moreno Martín-Retortillo, TACTIC: Explorando soluciones a los retos de salud mediante ciencia disruptiva, terapias avanzadas y medicina de sistemas, Josep Roma Castanyer, Laura Dos Subirá, Nicolás Miguel Fissolo, Maria Nazarena Pizzi, Tian Tian, Fernanda Raquel Da Silva Andrade, Diana Fernandes de Rafael, Andrea Guala
Entitat finançadora: Instituto de Salud Carlos III
Finançament: 2494527.53
Referència: FORT23/00034
Durada: 01/01/2024 - 31/12/2027